Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-Fv)  (BSGV-125)

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD64 antibody variable domain is fused to the C terminal of an IgG of anti-EGFR antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Datasheet